CJC-1295 / Ipamorelin

This product co-lyophilizes CJC-1295 (No-DAC / Modified GRF 1-29), a long-acting GHRH analogue, with Ipamorelin, a selective ghrelin-receptor (GHS-R1a) agonist. Because it is a mixture rather than a single molecule, it carries no single CAS number or formula; its research context is best read alongside the dedicated CJC-1295 and Ipamorelin listings.

GHRH analogues and GH-releasing peptides engage two different receptors on the pituitary somatotroph — the GHRH receptor and the GHS-R1a (ghrelin) receptor — and the research literature treats them as complementary inputs to GH release. [1][2] Pairing a long-acting GHRH analogue (which raises the underlying GHRH drive) with a selective GHRP (which triggers a discrete GH pulse) is therefore a common experimental design. This rationale is mechanistic and drawn from the separate single-agent literatures; controlled studies establishing a specific advantage of the combination are limited, and none support human use.

CJC-1295 is a modified GHRH(1-29) analogue engineered for prolonged GHRH-receptor activation; in healthy adults it produced sustained, dose-dependent increases in GH and IGF-1, amplifying the body's own pulsatile GH output. [1]

Ipamorelin is a pentapeptide and selective GHS-R1a (ghrelin-receptor) agonist that releases growth hormone with high selectivity — in its original characterisation it matched GHRP-6 for GH-releasing potency yet, unlike earlier GHRPs, did not significantly elevate ACTH or cortisol even at far higher doses. [2]

Both components are research compounds, and the overwhelming majority of supporting evidence comes from animal and in-vitro studies. This blend is supplied strictly for in-vitro and laboratory research by qualified professionals — it is not formulated, dosed, or authorised for use in humans or animals, and nothing here is a therapeutic claim.